BCL11A and cancer: Previous studies showed that high expression levels of PDGFC, SOX9, BCL11A, and DIO2 were associated with poor response to chemotherapy in cancer cells and short survival time of various patients, which could be regarded as negative prognostic factors (Bradley et al., 2018; Yin et al., 2019; Jana et al., 2020; Kim et al., 2021).